Windlas Biotech Limited
Windlas Biotech Limited is a Public Non-govt company company incorporated in 2001 and based in UR, India. Windlas Biotech Limited operates in Business Services (NIC 74899) with authorized capital of ₹77.50 Cr and paid-up capital of ₹10.90 Cr. For 2022-23, the company reported revenue of ₹513.08 Cr and profit after tax of ₹42.64 Cr. RegisterKaro's Compliance Health Score for the company is 35/100 (grade F), reflecting a weak compliance posture.
WINDLAS BIOTECH LIMITED is the legal entity of Windlas.
Quick facts
Directors
LockedDirectors, DINs & appointment history for Windlas Biotech Limited.
- Incorporation Documents
- Change in Directors & Designated Partner
- Board Resolutions
- Financial Statements & Annual Filings
- Charge Documents (Summary)
MCA Filings
Locked| Form | FY | Filed | Due | Delay | Status |
|---|---|---|---|---|---|
| AOC-4 | FY2024-25 | 30 Oct 2024 | 30 Oct 2024 | 0d | filed |
| MGT-7 | FY2024-25 | 22 Nov 2024 | 29 Nov 2024 | 0d | filed |
| AOC-4 | FY2023-24 | 30 Oct 2023 | 30 Oct 2023 | 0d | filed |
| MGT-7 | FY2023-24 | 20 Nov 2023 | 29 Nov 2023 | 0d | filed |
| AOC-4 | FY2022-23 | 30 Oct 2022 | 30 Oct 2022 | 0d | filed |
| MGT-7 | FY2022-23 | 26 Nov 2022 | 29 Nov 2022 | 0d | filed |
Full MCA filing history for Windlas Biotech Limited.
- Incorporation Documents
- Change in Directors & Designated Partner
- Board Resolutions
- Financial Statements & Annual Filings
- Charge Documents (Summary)
Charges
Locked| Charge ID | Holder | Amount | Created | Status |
|---|---|---|---|---|
| 737241162 | Kotak Mahindra Bank Ltd(Bank) | ₹22.75 Cr | 04 Jul 2022 | Open |
| 137714352 | State Bank of India(Bank) | ₹16.61 Cr | 12 Mar 2020 | Open |
| 420837749 | HDFC Bank Ltd(Bank) | ₹21.81 Cr | 12 Mar 2021 | Satisfied |
| 662283138 | State Bank of India(Bank) | ₹15.25 Cr | 19 Sep 2023 | Open |
| 982216640 | Axis Bank Ltd(Bank) | ₹10.42 Cr | 04 Jul 2019 | Open |
| 956095355 | Axis Bank Ltd(Bank) | ₹24.36 Cr | 27 Jan 2021 | Open |
Charge IDs, lenders & amounts for Windlas Biotech Limited.
- Incorporation Documents
- Change in Directors & Designated Partner
- Board Resolutions
- Financial Statements & Annual Filings
- Charge Documents (Summary)
Financial Performance
MCA| FY | Revenue | PAT | Net Worth | Total Assets | Employees |
|---|---|---|---|---|---|
| 2022-23 | — | ||||
| 2021-22 | — | ||||
| 2020-21 | — | ||||
| 2019-20 | — | ||||
| 2018-19 | — | ||||
| 2017-18 | — | ||||
| 2016-17 | — | ||||
| 2015-16 | — | ||||
| 2014-15 | — |
Detailed Financials
4 FYs| Line item | 2022-23 | 2021-22 | 2020-21 | 2019-20 |
|---|---|---|---|---|
| Income statement | ||||
| Revenue from operations | ||||
| Other income | ||||
| Total income | ||||
| Total expenses | ||||
| Profit before tax | ||||
| Profit / (Loss) after tax | ||||
| Balance sheet | ||||
| Equity / Net worth | ||||
| Borrowings | ||||
| Current liabilities | ||||
| Total liabilities | ||||
| Current assets | ||||
| Cash & equivalents | ||||
| Total assets | ||||
| Employees | — | — | — | — |
Cash-flow statement renders when the AOC-4 XBRL Cash Flow context is parsed during the extract phase.
Compounded Annual Growth Rate
| Metric | Latest value | 1Y CAGR | 3Y CAGR | 5Y CAGR |
|---|---|---|---|---|
| Revenue2022-23 | +85.0% | +74.0% | +5.0% | |
| Profit after Tax2022-23 | +64.0% | +68.0% | +36.0% | |
| Net Worth2022-23 | +8.0% | +49.0% | +70.0% |
Financial Ratios
| FY | Revenue | PAT | PAT margin | Rev growth | ROE | ROA | D/E | Rev/emp |
|---|---|---|---|---|---|---|---|---|
| 2014-15 | +2.15% | — | +8.72% | +2.74% | — | |||
| 2015-16 | +1.66% | +5.96% | +3.23% | +1.62% | — | |||
| 2016-17 | +2.87% | +16.11% | +6.12% | +3.02% | — | |||
| 2017-18 | +5.23% | +1.32% | +10.14% | +5.59% | — | |||
| 2018-19 | +7.74% | -10.15% | +11.58% | +7.57% | — | |||
| 2019-20 | +6.81% | +13.60% | +10.37% | +6.53% | — | |||
| 2020-21 | +1.17% | +29.65% | +2.52% | +1.69% | 0.49 | |||
| 2021-22 | +8.28% | +8.96% | +9.76% | +7.85% | 0.24 | |||
| 2022-23 | +8.31% | +10.12% | +10.59% | +8.06% | 0.31 |
Cap Table & Shareholding
Locked| Category | Shareholders | Shares held | % |
|---|---|---|---|
| Promoters | 2 | 44,01,147 | 77.08% |
| Institutional Investors | 3 | 2,80,079 | 4.91% |
| Public & Others | 32 | 10,28,824 | 18.02% |
Promoter, institutional & public holding for Windlas Biotech Limited.
- Incorporation Documents
- Change in Directors & Designated Partner
- Board Resolutions
- Financial Statements & Annual Filings
- Charge Documents (Summary)
Peer Benchmark
40251 peersEvents & timeline
3External data sources
7 plannedGSTIN Registrations
Per-state GSTINs + GSTR-1/3B filing cadence + turnover bracket. PAN-keyed scrape.
MSME Payment Delays
Half-yearly disclosure of payments delayed beyond 45 days to MSME suppliers.
Related Party Transactions
Counterparty, nature, transaction value. Inter-company loans, sales, royalty.
Credit Ratings
Long-term + short-term ratings, with rationale on rating actions.
Trademarks
Applied, registered, opposed. Class numbers + status.
Patents
Applications and grants. Inventor names + filing dates.
Legal Cases
Ongoing + past litigations the entity is party to.
Each source is wired as a separate ingestion adapter behind the scraper. Live status flips per CIN as records land.